Ionis Pharmaceuticals (IONS) said Monday the Committee for Medicinal Products for Human Use has recommended approval of the company and AstraZeneca's (AZN) Wainzua drug to treat hereditary transthyretin-mediated amyloidosis in the European Union.
The recommendation is for the treatment of adult patients with stage 1 or stage 2 polyneuropathy, the company said.
The recommendation was based on a phase 3 trial, which showed that patients treated with Wainzua "demonstrated consistent and sustained benefit on the co-primary endpoints of serum transthyretin concentration and neuropathy impairment," Ionis said.
Price: 39.30, Change: -0.38, Percent Change: -0.96
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.